Biomerieux Q3 Sales Up 7 Percent

Oct 20, 2016

NEW YORK (GenomeWeb) – Biomerieux reported today that its third quarter revenues rose 7 percent from Q3 2015, including a 46 percent jump in molecular biology sales.

For the quarter ended Sept. 30, the company reported total revenues of €510.8 million ($557.3 million) from €478.3 million a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biomerieux Q3 Sales Up 7 Percent

To read the full story....

Breaking News

FDA Adds At-Home Self-Collection Template to SARS-CoV-2 Emergency Use Authorization Guidance

BTIG Initiates Coverage of Fulgent Genetics

Tangen Biosciences, LabWare Partner on Point-of-Care Coronavirus Kit

Progenity Files for IPO, Seeks to Raise up to $100M

LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

OraSure Technologies to Acquire HIV Drug Adherence Test Developer UrSure

Featured White Papers

COVID-19 Testing, Treatment and Future Outlook

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

Progenity Files for IPO, Seeks to Raise up to $100M

Bio-Me Eyes PCR-Based Microbiome Profiling Technology for Future CDx

BioGX, Bosch Healthcare Solutions Partner to Develop Point-of-Care Infectious Disease Tests

SpectronRx Coronavirus Test Gets FDA Emergency Use Authorization

Sponsorships